Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 82 of the 83 references it cites were found in a registry or an index.
Abstract
The purpose of this study was to use serial imaging to gain insight into the sequence of pathologic events in Alzheimer's disease, and the clinical features associated with this sequence. We measured change in amyloid deposition over time using serial (11)C Pittsburgh compound B (PIB) positron emission tomography and progression of neurodegeneration using serial structural magnetic resonance imaging. We studied 21 healthy cognitively normal subjects, 32 with amnestic mild cognitive impairment and 8 with Alzheimer's disease. Subjects were drawn from two sources--ongoing longitudinal registries at Mayo Clinic, and the Alzheimer's disease Neuroimaging Initiative (ADNI). All subjects underwent clinical assessments, MRI and PIB studies at two time points, approximately one year apart. PIB retention was quantified in global cortical to cerebellar ratio units and brain atrophy in units of cm(3) by measuring ventricular expansion. The annual change in global PIB retention did not differ by clinical group (P = 0.90), and although small (median 0.042 ratio units/year overall) was greater than zero among all subjects (P < 0.001). Ventricular expansion rates differed by clinical group (P < 0.001) and increased in the following order: cognitively normal (1.3 cm(3)/year) < amnestic mild cognitive impairment (2.5 cm(3)/year) < Alzheimer's disease (7.7 cm(3)/year). Among all subjects there was no correlation between PIB change and concurrent change on CDR-SB (r = -0.01, P = 0.97) but some evidence of a weak correlation with MMSE (r =-0.22, P = 0.09). In contrast, greater rates of ventricular expansion were clearly correlated with worsening concurrent change on CDR-SB (r = 0.42, P < 0.01) and MMSE (r =-0.52, P < 0.01). Our data are consistent with a model of typical late onset Alzheimer's disease that has two main features: (i) dissociation between the rate of amyloid deposition and the rate of neurodegeneration late in life, with amyloid deposition proceeding at a constant slow rate while neurodegeneration accelerates and (ii) clinical symptoms are coupled to neurodegeneration not amyloid deposition. Significant plaque deposition occurs prior to clinical decline. The presence of brain amyloidosis alone is not sufficient to produce cognitive decline, rather, the neurodegenerative component of Alzheimer's disease pathology is the direct substrate of cognitive impairment and the rate of cognitive decline is driven by the rate of neurodegeneration. Neurodegeneration (atrophy on MRI) both precedes and parallels cognitive decline. This model implies a complimentary role for MRI and PIB imaging in Alzheimer's disease, with each reflecting one of the major pathologies, amyloid dysmetabolism and neurodegeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Efforts continue to be placed on the early detection of AD as changes in brain chemistry begin to occur 20 years or more prior to the onset of noticeable cognitive symptoms [137,138,139,140].”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [137]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although these symptoms are new to the individual affected, the brain changes that cause them are thought to begin 20 years or more before symptoms start.”
From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Studies of non-demented elderly cohorts overall report approximately 20–40% are PIB-positive [67, 68, 71–78].”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N., Mazoyer, B., & Joliot, M. (2002) · NeuroImage · doi:10.1006/nimg.2001.0978 · Cited by 16,319 · cited 1×
“The automated anatomic labelling (AAL) atlas (Tzourio-Mazoyer et al., 2002) was modified in-house to contain the following labelled regions of interest: right and left parietal, temporal, prefrontal, primary sensory -motor, orbito frontal, anterior cingulate, posterior cingulate/ precuneus and occipital.”
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
Hu, R. J. (2003) · Encyclopedia of the Neurological Sciences · doi:10.1016/b0-12-226870-9/01070-4 · Cited by 9,117
Diagnostic and Statistical Manual of Mental Disorders
Siegel, L. J., & Fletcher‐Janzem, E. (2008) · Encyclopedia of Special Education · doi:10.1002/9780470373699.speced0655 · Cited by 8,477
What's wrong with Bonferroni adjustments
Perneger, T. V. (1998) · BMJ · doi:10.1136/bmj.316.7139.1236 · Cited by 5,900
Current concepts in mild cognitive impairment
Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., Ritchie, K., Rossor, M., Thal, L., & Winblad, B. (2001) · Archives of Neurology · doi:10.1001/archneur.58.12.1985 · Cited by 4,781
Self-citation
Cited by
Items 401–500 of 1,000
Huang, K., Lin, K., Hsiao, I., Kuo, H., Hsu, W., Chuang, W., Kung, M., Wey, S., Hsieh, C., Wai, Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058974 · Cited by 61
Supporting evidence for using biomarkers in the diagnosis of MCI due to AD
Galluzzi, S., Geroldi, C., Amicucci, G., Bocchio‐Chiavetto, L., Bonetti, M., Bonvicini, C., Cotelli, M., Ghidoni, R., Paghera, B., Zanetti, O. O., et al. (2012) · Journal of Neurology · doi:10.1007/s00415-012-6694-0 · Cited by 62
Neuroimaging and its Relevance to Understanding Pathways Linking Diabetes and Cognitive Dysfunction
Moran, C., Beare, R. J., Phan, T. G., STARKSTEIN, S. E., Bruce, D. G., Mizrahi, R., & Srikanth, V. K. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161166 · Cited by 57
An Algorithm for Preclinical Diagnosis of Alzheimer's Disease
Khan, T. K. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00275 · Cited by 68
Dissociation between Brain Amyloid Deposition and Metabolism in Early Mild Cognitive Impairment
Wu, L., Rowley, J., Mohades, S., Leuzy, A., Dauar, M. T., Shin, M., Fonov, V., Jia, J., Gauthier, S. G., Rosa‐Neto, P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047905 · Cited by 56
Burstein, A. H., Zhao, Q., Ross, J., Styren, S. D., Landen, J. W., Ma, W. W., McCush, F., Alvey, C. W., Kupiec, J. W., & Bednar, M. M. (2013) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e318279bcfa · Cited by 57
Neuroimaging biomarkers in Alzheimer’s disease and other dementias
Villemagne, V. L., & Chételat, G. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.004 · Cited by 59
Rosenberg, P. B., Wong, D. F., Edell, S. L., Ross, J. S., Joshi, A. D., Brašić, J. R., Zhou, Y., Raymont, V., Kumar, A., Ravert, H. T., et al. (2013) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2012.11.016 · Cited by 54
Toward a multifactorial model of Alzheimer disease
Storandt, M., Head, D., Fagan, A. M., Holtzman, D. M., & Morris, J. C. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.11.029 · Cited by 53
Darst, B. F., Lu, Q., Johnson, S. C., & Engelman, C. D. (2019) · Genetic Epidemiology · doi:10.1002/gepi.22211 · Cited by 56
Brodtmann, A. G., Werden, E., Pardoe, H., Li, Q., Jackson, G. D., Donnan, G. A., Cowie, T., Bradshaw, J., Darby, D., & Cumming, T. B. (2014) · International Journal of Stroke · doi:10.1111/ijs.12301 · Cited by 55
Pires, R. H., Karsai, Á., Saraiva, M. J., Damas, A. M., & Kellermayer, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044992 · Cited by 53
How technology is reshaping cognitive assessment: Lessons from the Framingham Heart Study.
Au, R., Piers, R. J., & Devine, S. (2017) · Neuropsychology · doi:10.1037/neu0000411 · Cited by 49
Pandya, R., Nadiadwala, S., Shah, R., & Shah, M. (2019) · Augmented Human Research · doi:10.1007/s41133-019-0021-6 · Cited by 58
Revision of the criteria for Alzheimer's disease: A symposium
DeKosky, S. T., Carrillo, M. C., Phelps, C. H., Knopman, D. S., Petersen, R. C., Frank, R., Schenk, D., Masterman, D. M., Siemers, E., Cedarbaum, J. M., et al. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.12.007 · Cited by 57
Self-citationApplication of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI
Lowe, V. J., Peller, P. J., Weigand, S. D., Montoya Quintero, C., Tosakulwong, N., Vemuri, P., Senjem, M. L., Jordan, L., Jack, C. R., Knopman, D., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e318295d6cf · Cited by 50
Self-citationDiagnostic Biomarkers for Alzheimer’s Disease Using Non-Invasive Specimens
Paraskevaidi, M., Allsop, D., Karim, S., Martin, F. L., & Crean, S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061673 · Cited by 53
Duan, W., Zhou, G. D., Balachandrasekaran, A., Bhumkar, A. B., Boraste, P. B., Becker, J. T., Kuller, L. H., López, O. L., Gach, H. M., & Dai, W. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210199 · Cited by 54
Tosun, D., Initiative1, T. A. D. N., Schuff, N., Shaw, L. M., Trojanowski, J. Q., & Weiner, M. W. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-0006 · Cited by 52
Self-citationFunctional brain imaging of cognitive dysfunction in Parkinson's disease
Hirano, S., Shinotoh, H., & Eidelberg, D. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301818 · Cited by 55
Shi, J., Stonnington, C. M., Thompson, P. M., Chen, K., Gutman, B. A., Reschke, C., Baxter, L. C., Reiman, E. M., Caselli, R. J., & Wang, Y. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2014.09.062 · Cited by 53
The transitional association between β‐amyloid pathology and regional brain atrophy
Insel, P. S., Mattsson, N., Donohue, M., Mackin, R. S., Aisen, P. S. S., Jack, C. R., Shaw, L. M. J., Trojanowski, J. Q., Weiner, M. W., & Initiative, A. D. N. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.11.002 · Cited by 56
Self-citationNugent, S., Castellano, C., Goffaux, P., Whittingstall, K., Lepage, M., Paquet, N., Bocti, C., Fülöp, T., & Cunnane, S. C. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00067.2014 · Cited by 54
Pedrini, S., Thomas, C., Brautigam, H., Schmeidler, J., Ho, L., Fraser, P., Westaway, D., Hyslop, P. S., Martins, R. N., Buxbaum, J. D., et al. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-40 · Cited by 48
Pontecorvo, M. J., & Mintun, M. A. (2011) · Alzheimer's Research & Therapy · doi:10.1186/alzrt70 · Cited by 48
Association of vascular brain injury, neurodegeneration, amyloid, and cognitive trajectory
Han, J. W., Maillard, P., Harvey, D., Fletcher, E., Martinez, O., Johnson, D. K., Olichney, J. M., Farias, S. T., Villeneuve, S., Jagust, W., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010531 · Cited by 49
Ko, W. K. D., & Bézard, E. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.07.020 · Cited by 49
Yener, G., Emek‐Savaş, D. D., Lizio, R., Çavuşoğlu, B., Carducci, F., Ada, E., Güntekin, B., Babiloni, C., & Başar, E. (2015) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2015.02.005 · Cited by 50
Zarrouk, A., Nury, T., Samadi, M. H., O’Callaghan, Y. C., Hammami, M., O’Brien, N. M., Lizard, G., & Mackrill, J. J. (2015) · Steroids · doi:10.1016/j.steroids.2015.01.018 · Cited by 50
Mudar, R. A., Chiang, H., Eroh, J., Nguyen, L. T., Maguire, M. J., Spence, J. S., Kung, F., Kraut, M. A., & Hart, J. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150586 · Cited by 49
Chung, J. K., Plitman, E., Nakajima, S., Chakravarty, M. M., Caravaggio, F., Gerretsen, P., Iwata, Y., & Graff‐Guerrero, A. (2015) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988715606230 · Cited by 51
Alzheimer’s disease: amyloid-based pathogenesis and potential therapies
Zhou, Y., Sun, Y., Ma, Q., & Liu, Y. (2018) · Cell Stress · doi:10.15698/cst2018.07.143 · Cited by 53
Nootropic medicinal plants: Therapeutic alternatives for Alzheimer’s disease
Vyas, S., Kothari, S. L., & Kachhwaha, S. (2019) · Journal of Herbal Medicine · doi:10.1016/j.hermed.2019.100291 · Cited by 44
Stefanovski, L., Meier, J. M., Pai, R. K., Triebkorn, P., Lett, T. A. P., Martin, L., Bülau, K., Hofmann‐Apitius, M., Solodkin, A., McIntosh, A. R., et al. (2021) · Frontiers in Neuroinformatics · doi:10.3389/fninf.2021.630172 · Cited by 55
Uncovering heterogeneous cognitive trajectories in mild cognitive impairment: a data-driven approach
Wang, X., Ye, T., Zhou, W., Zhang, J., & Initiative, A. D. N. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01205-w · Cited by 49
Neuroimaging Results Impose New Views on Alzheimer’s Disease—the Role of Amyloid Revised
Fjell, A. M., & Walhovd, K. B. (2011) · Molecular Neurobiology · doi:10.1007/s12035-011-8228-7 · Cited by 51
Leoni, V., & Caccia, C. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.03.015 · Cited by 53
Genetics of dementia: Update and guidelines for the clinician
Cohn‐Hokke, P. E., Elting, M. W., Pijnenburg, Y. A. L., & Swieten, J. C. V. (2012) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32080 · Cited by 53
Neuroimaging and the Search for a Cure for Alzheimer Disease
Petrella, J. R. (2013) · Radiology · doi:10.1148/radiol.13122503 · Cited by 52
Gu, Y., Razlighi, Q. R., Zahodne, L. B., Janicki, S. C., Ichise, M., Manly, J. J., Devanand, D. P., Brickman, A. M., Schupf, N., Mayeux, R. P., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123743 · Cited by 50
Advances in Brain Amyloid Imaging
Krishnadas, N., Villemagne, V. L., Doré, V., & Rowe, C. C. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.12.005 · Cited by 47
Kennedy, K. M., & Raz, N. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-397025-1.00068-3 · Cited by 58
Spoken language biomarkers for detecting cognitive impairment
Alhanai, T., Au, R., & Glass, J. R. (2017) · IEEE Workshop on Automatic Speech Recognition and Understanding (ASRU) · doi:10.1109/asru.2017.8268965 · Cited by 54
Added Diagnostic Value of 11C-PiB-PET in Memory Clinic Patients with Uncertain Diagnosis
Frederiksen, K. S., Hasselbalch, S. G., Hejl, A., Law, I. G., Højgaard, L. D., & Waldemar, G. (2012) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000345783 · Cited by 49
Aβ-related hyperactivation in frontoparietal control regions in cognitively normal elderly
Oh, H., Steffener, J., Razlighi, Q. R., Habeck, C. G., Liu, D., Gazes, Y., Janicki, S. C., & Stern, Y. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.08.016 · Cited by 52
Metabolic Abnormalities of Erythrocytes as a Risk Factor for Alzheimer's Disease
Kosenko, E. A., Tikhonova, L. A., Montoliu, C., Barreto, G. E., Aliev, G., & Kaminsky, Y. G. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00728 · Cited by 48
Amyloid PET imaging in clinical practice
Kolanko, M. A., Win, Z., Loreto, F., Patel, N., Carswell, C., Gontsarova, A., Perry, R. J., & Malhotra, P. A. (2020) · Practical Neurology · doi:10.1136/practneurol-2019-002468 · Cited by 44
What can imaging tell us about cognitive impairment and dementia?
Narayanan, L., & Murray, A. D. (2016) · World Journal of Radiology · doi:10.4329/wjr.v8.i3.240 · Cited by 48
Zammit, M. D., Tudorascu, D. L., Laymon, C. M., Hartley, S. L., Zaman, S. H., Ances, B. M., Johnson, S. C., Stone, C. K., Mathis, C. A., Klunk, W. E., et al. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.117728 · Cited by 48
The Cognitive Consequences of Structural Changes to the Aging Brain
Rodrigue, K. M., & Kennedy, K. M. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-380882-0.00005-x · Cited by 49
Förster, S., Yousefi, B. H., Wester, H.-J., Klupp, E., Rominger, A., Förstl, H., Kurz, A., Grimmer, T., & Drzezga, A. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2230-9 · Cited by 45
Ayton, S., & Bush, A. I. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101212 · Cited by 45
Lowe, V. J., Lundt, E., Knopman, D., Senjem, M. L., Gunter, J. L., Schwarz, C. G., Kemp, B. J., Jack, C. R., & Petersen, R. C. (2017) · NeuroImage: Clinical · doi:10.1016/j.nicl.2017.08.011 · Cited by 45
“Participants were drawn prospectively from the Mayo Clinic Study of Aging (MCSA) as described previously (Jack et al., 2009) or from volunteers responding to study advertisement.”
Self-citationCSF and Brain Structural Imaging Markers of the Alzheimer's Pathological Cascade
Yang, X., Tan, M., & Qiu, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047406 · Cited by 45
Fukui, Y., Yamashita, T., Hishikawa, N., Kurata, T., Sato, K., Omote, Y., Kono, S., Yunoki, T., Kawahara, Y., Hatanaka, N., et al. (2015) · Internal Medicine · doi:10.2169/internalmedicine.54.3931 · Cited by 46
Advances in tau-based drug discovery
Noble, W., Pooler, A. M., & Hanger, D. P. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.586690 · Cited by 44
Amyloid accumulation in Down syndrome measured with amyloid load
Zammit, M. D., Laymon, C. M., Betthauser, T. J., Cody, K. A., Tudorascu, D. L., Minhas, D. S., Sabbagh, M. N., Johnson, S. C., Zaman, S. H., Mathis, C. A., et al. (2020) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12020 · Cited by 43
Zhao, H., Li, X., Wu, W., Li, Z., Qian, L., Li, S., Zhang, B., & Xu, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130017 · Cited by 48
Why bother using non-human primate models of cognitive disorders in translational research?
Camus, S. M. J., Ko, W. K. D., Pioli, E. Y., & Bézard, E. (2015) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2015.06.012 · Cited by 45
Zhou, Y., & Lui, Y. W. (2013) · ISRN Geriatrics · doi:10.1155/2013/542080 · Cited by 44
Biomarkers for Predicting Cognitive Decline in those with Normal Cognition
Steenland, K., Initiative, A. D. N., Zhao, L., Goldstein, F. C., Cellar, J. S., & Lah, J. J. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-2014-131343 · Cited by 48
The biochemical aftermath of anti-amyloid immunotherapy
Maarouf, C. L., Daugs, I. D., Kokjohn, T. A., Kalback, W. M., Patton, R. L., Luehrs, D. C., Masliah, E., Nicoll, J. A., Sabbagh, M. N., Beach, T. G., et al. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-39 · Cited by 43
Kang, T. W., Jeon, S., Kim, H., Park, J. H., Yim, D., Lee, H.-R., Ju, J., Kim, M.-J., & Kim, J. (2016) · ACS Nano · doi:10.1021/acsnano.6b01495 · Cited by 44
Slade, D., Pun, J., Murray, K. A., & Eggins, S. (2018) · The Journal of Continuing Education in Nursing · doi:10.3928/00220124-20180613-09 · Cited by 44
Vernon, A. C., Ballard, C. G., & Modo, M. (2010) · Brain Research Reviews · doi:10.1016/j.brainresrev.2010.05.006 · Cited by 47
Evaluation of neuroprotective effect of glucagon‐like peptide 1 analogs using neuroimaging
Femminella, G. D., & Edison, P. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.012 · Cited by 41
Matsumura, K., Ono, M., Kitada, A., Watanabe, H., Yoshimura, M., Iikuni, S., Kimura, H., Okamoto, Y., Ihara, M., & Saji, H. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00440 · Cited by 44
Basselin, M., Ramadan, E., & Rapoport, S. I. (2011) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.12.001 · Cited by 45
Leinonen, V., Rinne, J. O., Virtanen, K. A., Eskola, O., Rummukainen, J., Huttunen, J., von und zu Fraunberg, M., Nerg, O., Koivisto, A. M., Rinne, J., et al. (2013) · European Journal of Neurology · doi:10.1111/ene.12102 · Cited by 42
Abnormalities of plasma cytokines and spleen in senile APP/PS1/Tau transgenic mouse model
Yang, S.-H., Kim, J., Lee, M. J., & Kim, Y. (2015) · Scientific Reports · doi:10.1038/srep15703 · Cited by 40
Teng, E., Kepe, V., Frautschy, S. A., Liu, J., Satyamurthy, N., Yang, F., Chen, P.-P., Cole, G. B., Jones, M. R., Huang, S.-C., et al. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.05.003 · Cited by 41
Polygenic Risk Scores in Neurodegenerative Diseases: a Review
Ibáñez, L., Farias, F., Dube, U., Mihindukulasuriya, K. A., & Harari, O. (2019) · Current Genetic Medicine Reports · doi:10.1007/s40142-019-0158-0 · Cited by 47
Dicks, E., Vermunt, L., van der Flier, W. M., Visser, P. J., Barkhof, F., Scheltens, P., & Tijms, B. M. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.101786 · Cited by 48
Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults
ten Kate, M., Visser, P. J., Bakardjian, H., Barkhof, F., Sikkes, S. A. M., van der Flier, W. M., Scheltens, P., Hampel, H., Habert, M.-O., Dubois, B., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00067 · Cited by 41
Staffaroni, A. M., Goh, S.-Y. M., Cobigo, Y., Ong, E., Lee, S. E., Casaletto, K. B., Wolf, A., Forsberg, L. K., Ghoshal, N., Graff-Radford, N. R., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.22847 · Cited by 41
Self-citationMosconi, L., (ADNI), F. T. A. D. N. I., Andrews, R. D., & Matthews, D. C. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-121867 · Cited by 41
Jensen, J. R., Cisek, K. K., Funk, K. E., Naphade, S. B., Schafer, K. N., & Kuret, J. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-0003 · Cited by 46
Zhang, B., Lin, L., & Wu, S. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201274 · Cited by 43
Tau and the fractionated default mode network in atypical Alzheimer’s disease
Putcha, D., Eckbo, R., Katsumi, Y., Dickerson, B. C., Touroutoglou, A., & Collins, J. A. (2022) · Brain Communications · doi:10.1093/braincomms/fcac055 · Cited by 42
Bonifacio, G., & Zamboni, G. (2016) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2015-133759 · Cited by 46
Five-year follow-up of 11C-PIB uptake in Alzheimer’s disease and MCI
Kemppainen, N. M., Scheinin, N. M., Koivunen, J., Johansson, J. J., Toivonen, J., Någren, K., Rokka, J., Karrasch, M., Parkkola, R. K., & Rinne, J. O. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2562-0 · Cited by 40
Thai, C., Lim, Y. Y., Villemagne, V. L., Laws, S. M., Ames, D., Ellis, K. A., Rainey-Smith, S. R., Martins, R. N., Masters, C. L., Rowe, C. C., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0139082 · Cited by 40
Lin, S.-Y., Lin, C., Hsieh, T.-J., Lin, C.-F., Chen, S.-H., Chao, Y., Chen, Y., Hsu, C.-C., & Kuo, L. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.101680 · Cited by 43
Lack of association between 11C-PiB and longitudinal brain atrophy in non-demented older individuals
Driscoll, I., Zhou, Y., An, Y., Sojkova, J., Davatzikos, C., Kraut, M. A., Ye, W., Ferrucci, L., Mathis, C. A., Klunk, W. E., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.12.008 · Cited by 37
Andersson, E., Lindblom, N., Janelidze, S., Salvadó, G., Gkanatsiou, E., Söderberg, L., Möller, C., Lannfelt, L., Ge, J., Hanrieder, J., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00810-8 · Cited by 41
Lim, Y. Y., Ellis, K. A., Harrington, K., Pietrzak, R. H., Gale, J., Ames, D., Bush, A. I., Darby, D., Martins, R. N., Masters, C. L., et al. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-121771 · Cited by 34
Weiner, M. W., Sadowsky, C., Saxton, J. A., Hofbauer, R. K., Graham, S. M., Yu, S. Y., Li, S., Hsu, H., Suhy, J., Fridman, M., et al. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.09.003 · Cited by 40
Self-citationClark, V. H., Resnick, S. M., Doshi, J., Beason-Held, L. L., Zhou, Y., Ferrucci, L., Wong, D. F., Kraut, M. A., & Davatzikos, C. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.01.010 · Cited by 37
Cho, S. M., Lee, S., Yang, S.-H., Kim, H. Y., Lee, M. J., Kim, H. V., Kim, J., Baek, S., Yun, J., Kim, D., et al. (2016) · Scientific Reports · doi:10.1038/srep20185 · Cited by 39
Pasquini, L., Initiative, A. D. N., Benson, G. S., Grothe, M. J., Utz, L., Myers, N. E., Yakushev, I. Y., Grimmer, T., Scherr, M., & Sorg, C. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170096 · Cited by 44
PET Agents in Dementia: An Overview
van Waarde, A., Marcolini, S., Deyn, P. P. D., & Dierckx, R. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.12.008 · Cited by 39
Brain age predicts long-term recovery in post-stroke aphasia
Kristinsson, S., Busby, N., Rorden, C., Newman‐Norlund, R., den Ouden, D., Magnúsdóttir, S., Hjaltason, H., Thors, H., Hillis, A. E., Kjartansson, Ó., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac252 · Cited by 41
Ghosh, U., Yau, W., Collinge, J., & Tycko, R. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111863118 · Cited by 40
Hartz, R. A., Ahuja, V. T., Sivaprakasam, P., Xiao, H., Krause, C., Clarke, W., Kish, K., Lewis, H. A., Szapiel, N., Ramu, R., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00133 · Cited by 38
Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease
Hirao, K., Pontone, G. M., & Smith, G. S. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.11.010 · Cited by 40
Wu, S. Z., Masurkar, A. V., & Balcer, L. J. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.572337 · Cited by 40
Mild cognitive impairment in Parkinson disease: heterogenous mechanisms
Jellinger, K. A. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0771-5 · Cited by 46
Neuroimaging Biomarkers for Psychosis
Hager, B. M., & Keshavan, M. S. (2015) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-015-0035-4 · Cited by 40
Autoregulation of Cerebral Blood Flow to Changes in Arterial Pressure in Mild Alzheimer's Disease
Zazulia, A. R., Videen, T. O., Morris, J. C., & Powers, W. J. (2010) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.135 · Cited by 40
What have Novel Imaging Techniques Revealed About Metabolism in the Aging Brain?
Lin, A., & Rothman, D. L. (2014) · Future Neurology · doi:10.2217/fnl.14.13 · Cited by 41
Metadata
- Authors
- Jack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., Weiner, M., & Petersen, R. C.
- Affiliations
- Mayo Clinic (US)
- San Francisco VA Medical Center (US)
- Corresponding author
- Jack, Clifford R.
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-03-31
- Volume
- 132
- Issue
- 5
- Pages
- 1355-1365
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC2677798
- OpenAlex
- W2133719476
- Cited by
- 1,099
- References
- 83
- Citations by year
- 2026: 29 · 2025: 28 · 2024: 34 · 2023: 51 · 2022: 45 · 2021: 49 · 2020: 60 · 2019: 54 · 2018: 62 · 2017: 46 · 2016: 56 · 2015: 69 · 2014: 73 · 2013: 94 · 2012: 116
- FWCI
- 71.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Brain (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Mayo Foundation for Medical Education and Research (AG16574)
- National Institute for Health and Care Research (NF-SI-0508-10123)
- National Institute on Aging (R01AG11378, P01AG010491, P50‐AG16574, U01AG06786, AG 024904, R01AG027342, U01AG006786, R01AG011378, P30AG019610, U19AG010483, P50AG016574)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, mild cognitive impairment, amyloid deposition, neurodegeneration, brain atrophy, ventriculomegaly, Pittsburgh compound B PET, serial imaging, amyloid plaques, cognitive decline, Alzheimer's Disease Neuroimaging Initiative, brain atrophy rate
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Aniline Compounds, Atrophy, Brain, Carbon Radioisotopes, Cognition Disorders, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Thiazoles, Time Factors, Case-Control Studies, Amyloid beta-Peptides, Statistics, Nonparametric, Radiopharmaceuticals, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.